Skip to main content

Antiobesity Effects of Lactobacillus paracasei Subsp. paracasei, L. casei 431 on High-Fat Diet-Induced Obese Rats.

  • 2023-07-01
  • Journal of Medicinal Food 26(7)
    • Y. Shin
    • J. Bae
    • Hye-Rin Cho
    • Patience Mahoro
    • Seon Hwa Kim
    • Min Ji Han
    • Min-Jung Bae

Abstract

Obesity is currently regarded as a global concern, and the key objectives of the global health strategy include its prevention and control. Probiotic supplementation can help achieve these objectives. This study aimed to assess whether a probiotic strain Lactobacillus paracasei ssp. paracasei, Lactobacillus casei 431 (henceforth, L. casei 431) possesses antiobesogenic properties. High-fat diet-induced obese Sprague-Dawley rats were treated with L. casei 431 for 10 weeks, and the outcomes were compared with those of rats treated with the antiobesity medication orlistat. Body weights, epididymal fat, and tissues from mice were assessed. Furthermore, serological and histological analyses were performed. Epididymal fat accumulation was significantly reduced in groups administered L. casei 431 and orlistat. Furthermore, L. casei 431 and orlistat treatments lowered serum alanine transaminase, aspartate aminotransferase, and triglyceride (TG) levels. Hematoxylin and eosin staining of the liver and epididymal adipose tissues showed that the L. casei 431-treated groups exhibited reduced lipid buildup and adipocyte size. Furthermore, sterol regulatory element-binding protein 1c, adipose TG lipase, and lipoprotein lipase messenger RNA (mRNA) levels were upregulated, leading to lipid oxidation and degradation, in L. casei 431-supplemented groups. Furthermore, carnitine palmitoyltransferase 1, a major factor in lipolysis, was consistently upregulated at the protein level after L. casei 431 administration. Collectively, these results demonstrate the potential of L. casei 431 in alleviating obesity in rats through optimizing lipid metabolism and some related biomarkers.

Keywords: L. casei 431; Lactobacillus paracasei subsp. paracasei; lipid oxidation; obesity; probiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus paracasei 431Increased CPT1 Protein LevelsBeneficial
Moderate
Lactobacillus paracasei 431Reduced Alanine Transaminase ActivityBeneficial
Moderate
Lactobacillus paracasei 431Reduced Aminotransferase LevelsBeneficial
Moderate
Lactobacillus paracasei 431Reduced Epididymal Fat MassBeneficial
Large
Lactobacillus paracasei subsp. paracasei UALs-04Increased CPT1 Protein LevelsBeneficial
Moderate
Lactobacillus paracasei subsp. paracasei UALs-04Reduced Alanine Transaminase ActivityBeneficial
Moderate
Lactobacillus paracasei subsp. paracasei UALs-04Reduced Aminotransferase LevelsBeneficial
Moderate
Lactobacillus paracasei subsp. paracasei UALs-04Reduced Epididymal Fat MassBeneficial
Large
Lactobacillus paracasei subsp. paracasei UALs-04Reduced Serum Triglyceride LevelsBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.